SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Pharmova soars as its arm gets EIR from USFDA for radiopharmaceuticals manufacturing facility Montreal Canada

29 Aug 2022 Evaluate

Jubilant Pharmova is currently trading at Rs. 348.65, up by 11.75 points or 3.49% from its previous closing of Rs. 336.90 on the BSE.

The scrip opened at Rs. 340.00 and has touched a high and low of Rs. 350.00 and Rs. 335.40 respectively. So far 28764 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 690.00 on 01-Sep-2021 and a 52 week low of Rs. 317.65 on 21-Jun-2022.

Last one week high and low of the scrip stood at Rs. 350.00 and Rs. 335.40 respectively. The current market cap of the company is Rs. 5366.18 crore.

The promoters holding in the company stood at 50.68%, while Institutions and Non-Institutions held 24.09% and 25.24% respectively.

Jubilant Pharmova’s wholly owned subsidiary -- Jubilant Draximage Inc., has received the Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for its radiopharmaceuticals manufacturing facility at Montreal Canada in respect of the inspection conducted by the regulatory agency from June 6, 2022 to June 10, 2022. With the receipt of the EIR, the inspection stands successfully closed.

Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.

Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×